CN Bio Innovations develops human organ-on-chip technologies: devices that enable the formation of miniature models of human organs in the lab. We provide products and services to the pharmaceutical industry and in the past 3 years have used our proprietary organ-on-chip models in drug discovery and drug safety programs with more than 25 pharmaceutical companies. CN Bio has also pursued research to develop disease organ-on-chip models with successful programmes resulting in novel models of non-alcoholic steatohepatitis and Hepatitis B virus infection.
Working closely with academic pioneers in the bio-engineering field, and pharmaceutical and industrial partners, CN Bio Innovations continues to advance next generation human Organs-on-Chips.
CN Bio Innovations was a co-recipient with the Massachusetts Institute of Technology in 2012 of a $26M US government contract (DARPA) to develop a “body-on-a-chip”. In March 2018, Nature Scientific Reports published details of the successful final milestone of this program: completion of a platform connecting engineered tissues from 10 organs. This technology allows researchers to accurately replicate human organ interactions for weeks at a time and to measure the systemic effects of drugs on the body.
CN Bio’s Organs-on-chip devices are designed to recreate the physiological and mechanical micro-environment of human organs.
CN Bio’s Organs-on-Chips permit long-term culture of primary human cells, iPSC and cell lines enabling novel biology and pharmacology research.
Disease organ-on-chips can be created using physiological stimuli which ensure that the deep biology (signalling pathways, target proteins) is truly representative of the human disease.